Cough in Idiopathic Pulmonary Fibrosis Pipeline: 5+ Trailblazing Companies Advancing the Next Generation of Innovative Treatments | DelveInsight

The IPF cough therapy segment is gaining serious momentum, with players like Trevi Therapeutics, Cellular Sciences/Emphycorp, NeRRe Therapeutics, and Algernon Pharmaceuticals leveraging novel neuromodulatory approaches to tackle chronic cough-a symptom long underserved in pulmonary care. These advancements signal a shift toward symptom-focused, patient-centric innovation in rare respiratory disorders.

DelveInsight's "Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the cough in idiopathic pulmonary fibrosis market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging cough in idiopathic pulmonary fibrosis drugs, the cough in idiopathic pulmonary fibrosis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report
• DelveInsight's cough in idiopathic pulmonary fibrosis pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline drugs for cough in idiopathic pulmonary fibrosis treatment.
• The leading cough in idiopathic pulmonary fibrosis companies include Trevi Therapeutics, Cellular Sciences/Emphycorp, NeRRe Therapeutics, Algernon Pharmaceuticals, Melius Pharma, and others are evaluating their lead assets to improve the cough in idiopathic pulmonary fibrosis treatment landscape.
• Key cough in idiopathic pulmonary fibrosis pipeline therapies in various stages of development include Haduvio (nalbuphine ER), Ifenprodi, ME-015, and others.
• In February 2025, Boehringer Ingelheim revealed that its FIBRONEERTM-ILD trial also achieved its primary endpoint, showing improved FVC in patients with ILD, while maintaining a favorable safety and tolerability profile consistent with earlier IPF studies.
• In September 2024, Boehringer Ingelheim announced that its FIBRONEERTM-IPF trial-the largest IPF study to date-met its primary endpoint, demonstrating a significant improvement in Forced Vital Capacity (FVC) at week 52 versus placebo. The trial enrolled patients across 330+ sites in over 30 countries.
• In May 2024, Pliant Therapeutics reported positive topline results from a 12-week randomized, double-blind, placebo-controlled trial of bexotegrast (PLN-74809) at Massachusetts General Hospital, showing reductions in total lung collagen levels in patients with idiopathic pulmonary fibrosis (IPF).
• In December 2023, Trevi Therapeutics initiated its Phase IIb CORAL trial to evaluate HaduvioTM (oral nalbuphine ER) across three dose levels versus placebo in approximately 160 IPF patients with chronic cough.

Request a sample and discover the recent breakthroughs happening in the cough in idiopathic pulmonary fibrosis pipeline landscape @ https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cough in Idiopathic Pulmonary Fibrosis Overview
Chronic cough is a frequent and distressing symptom in patients with idiopathic pulmonary fibrosis (IPF), affecting up to 80% of individuals with the disease. This dry, persistent cough worsens over time and results from a combination of lung changes, such as mucous production and lung distortion, as well as increased cough reflex sensitivity. Comorbidities like gastroesophageal reflux disease (GERD), obstructive sleep apnea (OSA), and chronic sinusitis can also contribute. Despite no approved treatments for IPF cough, management options include proton pump inhibitors, inhaled steroids, and opioids like morphine.

Cough in IPF is often persistent and dry, typically resistant to over-the-counter treatments, significantly impacting the quality of life. Diagnosis of IPF involves evaluating symptoms like dry cough, exertional dyspnea, and bibasilar crackles. Imaging tests like high-resolution CT (HRCT) and pulmonary function tests (PFTs), along with excluding other interstitial lung diseases (ILDs), are key for accurate diagnosis and treatment planning.

Find out more about cough in idiopathic pulmonary fibrosis medication @ https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cough in Idiopathic Pulmonary Fibrosis Treatment Analysis: Drug Profile
Haduvio (nalbuphine ER): Trevi Therapeutics

Haduvio (nalbuphine ER) offers a unique mechanism for treating chronic cough by targeting key receptors involved in both central and peripheral cough pathways. It functions as a kappa opioid receptor agonist and a mu opioid receptor antagonist, enabling it to modulate the entire cough reflex arc-regardless of whether the cough originates in the lungs or the central nervous system. The therapy is currently being evaluated in a Phase II clinical trial for managing cough in patients with Idiopathic Pulmonary Fibrosis (IPF).

Orvepitant Maleate: NeRRe Therapeutics
Orvepitant Maleate is a selective NK-1 receptor antagonist developed by NeRRe Therapeutics, designed to reduce central neural hypersensitivity by blocking the action of substance P. This dual peripheral and central mechanism targets chronic cough effectively. Following promising results in patients with refractory or unexplained chronic cough, the drug is now in Phase II clinical trials to assess its efficacy in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF).

Key Cough in Idiopathic Pulmonary Fibrosis Therapies and Companies
• Haduvio (nalbuphine ER): Trevi Therapeutics
• Orvepitant Maleate: NeRRe Therapeutics
• Haduvio (Nalbuphine ER): Trevi Therapeutics
• Ifenprodil (NP-120): Algernon Pharmaceuticals/Seyltx Inc.
• ME-015 (Suplatast Tosilate): Melius Pharma AB
• Sodium pyruvate (N115): Cellular Sciences/Emphycorp

Learn more about the novel and emerging cough in idiopathic pulmonary fibrosis pipeline therapies @ https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cough in Idiopathic Pulmonary Fibrosis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report
• Coverage: Global
• Key Cough in Idiopathic Pulmonary Fibrosis Companies: Trevi Therapeutics, Cellular Sciences/Emphycorp, NeRRe Therapeutics, Algernon Pharmaceuticals, Melius Pharma, and others.
• Key Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapies: Haduvio (nalbuphine ER), Ifenprodi, ME-015, others.

Dive deep into rich insights for drugs used for cough in idiopathic pulmonary fibrosis treatment; visit @ https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Cough in Idiopathic Pulmonary Fibrosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics
6. Cough in Idiopathic Pulmonary Fibrosis Pipeline: Late-Stage Products (Phase III)
7. Cough in Idiopathic Pulmonary Fibrosis Pipeline: Mid-Stage Products (Phase II)
8. Cough in Idiopathic Pulmonary Fibrosis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. Through our subscription-based platform, PharmDelve, you can get hassle-free access to all the healthcare and pharmaceutical market research reports.

This release was published on openPR.